Mometasone furoate dry-powder inhaler for the control of persistent asthma

Bibliography

• MASOLI M, FABIAN D, HOLT S, BEASLEY R: Global Burden of Asthma. Medical Research Institute of New Zealand (2004).
   Google Scholar
• BRAMAN SS: The global burden of asthma. Chest Surg. Clin. North Am. (2006) 130(Suppl. 1):S4-S12.
   Google Scholar
• NATIONAL CENTER FOR HEALTH STATISTICS: Asthma Prevalence, Health Care Use and Mortality. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics (2002).
   Google Scholar
• BARNES PJ, PEDERSEN S, BUSSE WW: Efficacy and safety of inhaled corticosteroids. New developments. Am. J. Respir. Crit. Care Med. (1998) 157(3 Part 2):S1-S53.
   PubMed Web of Science ®Google Scholar
• SUISSA S, ERNST P, BENAYOUN S, BALTZAN M, CAI B: Low-dose inhaled corticosteroids and the prevention of death from asthma. N. Engl. J. Med. (2000) 343(5):332-336.
   PubMed Web of Science ®Google Scholar
• ABDULLAH AK, KHAN S: Evidence-based selection of inhaled corticosteroid for treatment of chronic asthma. J. Asthma (2007) 44(1):1-12.
   PubMed Web of Science ®Google Scholar
• YANG TT, LI S, WYKA B, KENYON D: Drug delivery performance of the mometasone furoate dry powder inhaler. J. Aerosol. Med. (2001) 14(4):487-494.
   PubMedGoogle Scholar
• SAHASRANAMAN S, ISSAR M, HOCHHAUS G: Metabolism of mometasone furoate and biological activity of the metabolites. Drug Metab. Dispos. (2006) 34(2):225-233.
   PubMed Web of Science ®Google Scholar
• PATRADOON-HO P, GUNASEKERA H, RYAN MM, AMBLER GR: Inhaled corticosteroids, adrenal suppression and benign intracranial hypertension. Med. J. Aust. (2006) 185(5):279-280.
   PubMed Web of Science ®Google Scholar
• KUNA P, PETERS MJ, MANJRA AI et al.: Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int. J. Clin. Pract. (2007) 61(5):725-736.
   PubMed Web of Science ®Google Scholar
• ASMANEX® TWISTHALER® (MOMETASONE FUROATE INHALATION POWDER): Full Prescribing Information, Schering Corporation, Kenilworth, NJ (2005).
   Google Scholar
• SMITH CL, KREUTNER W: In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneim-Forsch (1998) 48(9):956-960.
   PubMed Web of Science ®Google Scholar
• AUSTIN RJ, MASCHERA B, WALKER A et al.: Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur. Respir. J. (2002) 20(6):1386-1392.
   PubMed Web of Science ®Google Scholar
• KARPEL JP: An easy-to-use dry-powder inhaler. Adv. Ther. (2000) 17(6):282-286.
   PubMed Web of Science ®Google Scholar
• WARDLAW A, LARIVEE P, ELLER J et al.: Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate. Ann. Allergy Asthma Immunol. (2004) 93(1):49-55.
   PubMed Web of Science ®Google Scholar
• CHRYSTYN H: Is total particle dose more important than particle distribution? Respir. Med. (1997) 91(Suppl. A):17-19.
   PubMed Web of Science ®Google Scholar
• BARTON BE, JAKWAY JP, SMITH SR, SIEGEL MI: Cytokine inhibition by a novel steroid, mometasone furoate. Immunopharmacol. Immunotoxicol. (1991) 13(3):251-261.
   PubMed Web of Science ®Google Scholar
• STELLATO C, ATSUTA J, BICKEL CA, SCHLEIMER RP: An in vitro comparison of commonly used topical glucocorticoid preparations. J. Allergy Clin. Immunol. (1999) 104(3 Part 1):623-629.
   PubMed Web of Science ®Google Scholar
• ZHANG X, MOILANEN E, ADCOCK IM, LINDSAY MA, KANKAANRANTA H: Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. Life Sci. (2002) 71(13):1523-1534.
   PubMed Web of Science ®Google Scholar
• INMAN MD, WATSON RM, RERECICH T et al.: Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am. J. Respir. Crit. Care Med. (2001) 164(4):569-574.
   PubMed Web of Science ®Google Scholar
• AFFRIME MB, CUSS F, PADHI D et al.: Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J. Clin. Pharmacol. (2000) 40(11):1227-1236.
   PubMed Web of Science ®Google Scholar
• DALEY-YATES P, DERKS M, WEEKS A et al.: Pharmacokinetics and pharmacodynamics of fluticasone propionate and mometasone furoate dry powder inhalers in healthy and asthmatic subjects [Abstr. B35 plus poster G25]. The 101st International Conference of the American Thoracic Society. San Diego, CA (20 – 25 May 2005).
   Google Scholar
• AFFRIME M, KOSOGLOU T: The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild to moderate persistent asthma [Abstract 346]. J. Allergy Clin. Immunol. (2001) 107(Suppl.):S104.
   Web of Science ®Google Scholar
• CRIM C, PIERRE LN, DALEY-YATES PT: A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin. Ther. (2001) 23(9):1339-1354.
   PubMed Web of Science ®Google Scholar
• MORTIMER KJ, HARRISON TW, TANG Y et al.: Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. Br. J. Clin. Pharmacol. (2006) 62(4):412-419.
   PubMed Web of Science ®Google Scholar
• AFFRIME MB, KOSOGLOU T, THONOOR CM, FLANNERY BE, HERRON JM: Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest (2000) 118(6):1538-1546.
   PubMed Web of Science ®Google Scholar
• NAYAK AS, BANOV C, CORREN J et al.: Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann. Allergy Asthma Immunol. (2000) 84(4):417-424.
   PubMed Web of Science ®Google Scholar
• KEMP JP, BERKOWITZ RB, MILLER SD et al.: Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J. Allergy Clin. Immunol. (2000) 106(3):485-492.
   PubMed Web of Science ®Google Scholar
• FISH JE, KARPEL JP, CRAIG TJ et al.: Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J. Allergy Clin. Immunol. (2000) 106(5):852-860.
   PubMed Web of Science ®Google Scholar
• NOONAN M, KARPEL JP, BENSCH GW et al.: Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann. Allergy Asthma Immunol. (2001) 86(1):36-43.
   PubMed Web of Science ®Google Scholar
• D'URZO A, KARPEL JP, BUSSE WW et al.: Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr. Med. Res. Opin. (2005) 21(8):1281-1289.
   PubMed Web of Science ®Google Scholar
• KARPEL JP, BUSSE WW, NOONAN MJ et al.: Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. Ann. Pharmacother. (2005) 39(12):1977-1983.
   PubMed Web of Science ®Google Scholar
• BENSCH GW, PRENNER B, BERKOWITZ R et al.: Once-daily evening administration of mometasone furoate in asthma treatment initiation. Ann. Allergy Asthma Immunol. (2006) 96(4):533-540.
   PubMed Web of Science ®Google Scholar
• BERNSTEIN DI, BERKOWITZ RB, CHERVINSKY P et al.: Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir. Med. (1999) 93(9):603-612.
   PubMed Web of Science ®Google Scholar
• BOUSQUET J, D'URZO A, HEBERT J et al.: Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur. Respir. J. (2000) 16(5):808-816.
   PubMed Web of Science ®Google Scholar
• NATHAN RA, NAYAK AS, GRAFT DF et al.: Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann. Allergy Asthma Immunol. (2001) 86(2):203-210.
   PubMed Web of Science ®Google Scholar
• O'CONNOR B, BONNAUD G, HAAHTELA T et al.: Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann. Allergy Asthma Immunol. (2001) 86(4):397-404.
   PubMed Web of Science ®Google Scholar
• CORREN J, BERKOWITZ R, MURRAY JJ, PRENNER B: Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Int. J. Clin. Pract. (2003) 57(7):567-572.
   PubMed Web of Science ®Google Scholar
• BERGER WE, MILGROM H, CHERVINSKY P et al.: Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma. Ann. Allergy Asthma Immunol. (2006) 97(5):672-680.
   PubMed Web of Science ®Google Scholar
• LEMANSKE R, LOCKEY R, MURPHY K: Effects of one year of treatment with mometasone furoate metered dose inhaler (MF-MDI) on growth in children with asthma (Abstract). Eur. Respir. J. (2004) 24:S378.
   PubMed Web of Science ®Google Scholar
• MELTZER EO, BAENA-CAGNANI CE, CHERVINSKY P et al.: Once-daily mometasone furoate administered by dry powder inhaler for the treatment of children with persistent asthma. Pediatr. Asthma Allergy Immunol. (2007) 20(2):67-81.
   Google Scholar
• FLOVENT® HFA (FLUTICASONE PROPIONATE): Full Prescribing Information, GlaxoSmithKline, Research Triangle Park, NC (2005).
   Google Scholar
• PULMICORT TURBUHALER® (BUDESONIDE INHALATION POWDER): Full Prescribing Information, AstraZeneca Pharmaceuticals LP, Wilmington, DE (2003).
   Google Scholar
• QVAR® (BECLOMETHASONE DIPROPIONATE): Full prescribing information, IVAX laboratories, Inc., Miami, FL (2002).
   Google Scholar
• NAYAK AS, LAMPL KL, SEGALL N, HARRISON JE, C96-136 STUDY GROUP: Long-term use of once-daily mometasone furoate is effective and well tolerated in patients with mild to moderate persistent asthma. 57th Annual Meeting of the American Academy of Allergy, Asthma and Immunology. New Orleans, LA (16 – 21 March 2001).
   Google Scholar
• MURRAY J, BUSSE W, DOCKHORN R, PICONE F, HARRISON J: Long-term safety of mometasone furoate (MF) administered by dry powder inhaler (DPI) in patients with moderate persistent asthma. Eur. Respir. J. (2000) 16:280S-281S.
   Google Scholar
• ALLEN DB, BIELORY L, DERENDORF H et al.: Inhaled corticosteroids: past lessons and future issues. J. Allergy Clin. Immunol. (2003) 112(3 Suppl.):S1-S40.
   PubMedGoogle Scholar
• DERENDORF H, DALEY-YATES PT, PIERRE LN, EFTHIMIOU J: Bioavailability and metabolism of mometasone furoate: pharmacology versus methodology. J. Clin. Pharmacol. (2002) 42(4):383-387.
   PubMed Web of Science ®Google Scholar
• FARDON TC, LEE DK, HAGGART K, MCFARLANE LC, LIPWORTH BJ: Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am. J. Respir. Crit. Care Med. (2004) 170(9):960-966.
   PubMed Web of Science ®Google Scholar
• CHROUSOS GP, GHALY L, SHEDDEN A, IEZZONI DG, HARRIS AG: Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chest (2005) 128(1):70-77.
   PubMed Web of Science ®Google Scholar
• SKONER D, DUNN M, LEE T: Effects of mometasone furoate dry powder inhaler on growth velocity and hypothalamic-pituitary-adrenal axis function in children with asthma (Abstract). Am. J. Respir. Crit. Care Med. (2003) 167:A272.
   Google Scholar
• LEONE FT, FISH JE, SZEFLER SJ, WEST SL: Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American college of chest physicians, American academy of allergy, asthma, and immunology, and American college of allergy, asthma, and immunology. Chest (2003) 124(6):2329-2340.
   PubMed Web of Science ®Google Scholar
• O'BYRNE PM, BARNES PJ, RODRIGUEZ-ROISIN R et al.: Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am. J. Respir. Crit. Care Med. (2001) 164(8 Part 1):1392-1397.
   PubMed Web of Science ®Google Scholar
• BATEMAN ED, BOUSHEY HA, BOUSQUET J et al.: Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am. J. Respir. Crit. Care Med. (2004) 170(8):836-844.
   PubMed Web of Science ®Google Scholar
• MCIVOR RA, PIZZICHINI E, TURNER MO et al.: Potential masking effects of salmeterol on airway inflammation in asthma. Am. J. Respir. Crit. Care Med. (1998) 158(3):924-930.
   PubMed Web of Science ®Google Scholar
• SEREVENT® DISKUS® (SALMETEROL XINAFOATE INHALATION POWDER): Full Prescribing Information, GlaxoSmithKline, Research Triangle Park, NC (2006).
   Google Scholar
• FORADIL® AEROLIZER® (FORMOTEROL FUMARATE INHALATION POWDER): Full Prescribing Information, Novartis Pharma AG/Schering Corporation, Kenilworth, NJ (2006).
   Google Scholar
• BEEH KM, DEROM E, KANNIESS F et al.: Indacaterol, a novel inhaled β2-agonist, provides sustained 24-h bronchodilation in asthma. Eur. Respir. J. (2007) 29(5):871-878.
   PubMed Web of Science ®Google Scholar
• ARGENTI D, SHAH B, HEALD D: A pharmacokinetic study to evaluate the absolute bioavailability of triamcinolone acetonide following inhalation administration. J. Clin. Pharmacol. (1999) 39(7):695-702.
   PubMed Web of Science ®Google Scholar